Table I.
Characteristics of patients with de novo AML and t-AML.
| Characteristic | De novo AML, n (%) | t-AML, n (%) | P-value |
|---|---|---|---|
| Total | 193 (83.5) | 38 (16.5) | |
| Gender | |||
| Male | 86 | 11 | 0.08* |
| Female | 107 | 27 | |
| Age, years (range) | 50 (15–78) | 56 (17–78) | <0.000+ |
| Cytogenetics | |||
| Abnormal | 74 (46.6) | 27 (94.7) | 0.009* |
| Normal | 77 (39.9) | 9 (23.7) | |
| Missing | 26 (13.5) | 2 (5.3) | |
| CBF | 53 (27.5) | 17 (44.7) | <0.000* |
| 5,7 and 8 alterations | 13 (6.7) | 3 (7.9) | 0.912* |
| t(9,11) | 8 (4.1) | 2 (5.3) | 0.845* |
| Complex | 16 (8.3) | 5 (13.2) | 0.441* |
| SWOG risk score | |||
| Favorable | 56 (30.3) | 9 (23.7) | 0.656* |
| Intermediate | 97 (52.4) | 14 (36.8) | 0.228* |
| Unfavorable | 32 (17.3) | 11 (28.9) | 0.042* |
| Complete response | 150 (84.3) | 26 (68.4) | 0.872* |
*
χ2 test
+
t test. AML, acute myeloid leukemia; t-AML, therapy-related acute myeloid leukemia; CBF, core-binding factor; SWOG, Southwest Oncology Group.